Business Daily Media

Times Advertising

.

Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020

  • Written by ACN Newswire - Press Releases

Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020

TOKYO, Sep 18, 2020 - (JCN Newswire) - Eisai Co., Ltd. has announced that the latest results from the cohort targeting patients with HER2-negative breast cancer in phase I clinical trial for the new liposomal formulation (E7389-LF) of the in-house discovered anti-cancer treatment Halaven (generic name: eribulin mesylate, "eribulin") were

Read more //?#

BizCover Brings Australia’s First AI-Based Insurance Quotes to ChatGPT

Australian small business owners can now receive and compare business insurance quotes directly inside ChatGPT, in a move that signals a major shi...

VistaPrint Research Reveals Australian Small Businesses Face a Succession Cliff

With only 16% of retiring small businesses having a succession plan, tens of thousands risk closure as one in three owners nears retirement.  Ne...

Corporate volunteering grows up: how companies are shifting to meaningful, community-led impact

As workplaces settle into the new year and look for ways to strengthen culture, capability and connection, experts say corporate volunteering is e...

The Rise of Mobile-First Venues

Global Hospitality Platform, Tabit, Reveals Five Ways to Maximise Benefits of Mobile-First Systems  As Australian hospitality venues grapple with...

Why the SME is now the primary engine of global cybercrime

For over a decade, the most practical and effective advice we could offer an employee was to spot the typo. It was practical, it was free, and it wo...

Work-life Balance Key to Solving Construction Talent Shortage

New data from leading talent company Randstad Australia shows flexible working and work-life balance could be critical to addressing ongoing talen...